Eupraxia Pharmaceuticals (TSX:EPRX) Research & Development: C$39.40 Mil (TTM As of Mar. 2026)


TSX:EPRX Eupraxia Pharmaceuticals Inc TSX:EPRX
37 GF Score
Price C$9.38
! 1 Warning Sign
View Full Analysis

What is Eupraxia Pharmaceuticals Research & Development?

Eupraxia Pharmaceuticals TSX:EPRX +2.85% 37 Research & Development is C$39.40 Mil as of Mar. 2026. GuruFocus rates TSX:EPRX with a GF Score™ of 37/100. The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Eupraxia Pharmaceuticals's Research & Development for the three months ended in Mar. 2026 was C$15.33 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was C$39.40 Mil.

Eupraxia Pharmaceuticals  (TSX:EPRX) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Eupraxia Pharmaceuticals Research & Development Related Terms

Eupraxia Pharmaceuticals Research & Development Historical Data

* Premium members only.

The historical data trend for Eupraxia Pharmaceuticals's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eupraxia Pharmaceuticals Research & Development Chart

Eupraxia Pharmaceuticals Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only 9.72 18.52 27.32 22.91 29.43

Eupraxia Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.53 7.10 6.11 10.85 15.33
TSX:EPRX
37GF Score
Eupraxia Pharmaceuticals Inc TSX:EPRX
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eupraxia Pharmaceuticals Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$39.40 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of C$39.40 Mil mean?
Eupraxia Pharmaceuticals (TSX:EPRX) has a Research & Development of C$39.40 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Eupraxia Pharmaceuticals and its competitors.
Is Eupraxia Pharmaceuticals' Research & Development too high?
Eupraxia Pharmaceuticals' current Research & Development is C$39.40 Mil. Overall, Eupraxia Pharmaceuticals has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Eupraxia Pharmaceuticals' Research & Development compare to VRTX and REGN?
Eupraxia Pharmaceuticals' Research & Development of C$39.40 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Eupraxia Pharmaceuticals and its competitors. Eupraxia Pharmaceuticals's current Research & Development is C$39.40 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eupraxia Pharmaceuticals stock overvalued right now?
Eupraxia Pharmaceuticals (TSX:EPRX) has a current Research & Development of C$39.40 Mil. The current Research & Development is C$39.40 Mil. Eupraxia Pharmaceuticals' overall GF Score™ is 37/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Eupraxia Pharmaceuticals (TSX:EPRX), the current Research & Development is C$39.40 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Eupraxia Pharmaceuticals Business Description

Other Exchanges EPRX:USAX43:Germany
Address 201 2067 Cadboro Bay Road, Victoria, BC, CAN, V8R 5G4
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs. Currently, the company has two distinct clinical development programs, one targeting EoE and the second targeting chronic Osteoarthritis pain in the knee and has completed a Phase 2b clinical trial with EP-104IAR in knee OA.
37GF Score

Get the complete analysis for TSX:EPRX

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$9.38
Price